[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BG103808A - Methods and compositions for modulation responsiveness to corticosteroids - Google Patents

Methods and compositions for modulation responsiveness to corticosteroids

Info

Publication number
BG103808A
BG103808A BG103808A BG10380899A BG103808A BG 103808 A BG103808 A BG 103808A BG 103808 A BG103808 A BG 103808A BG 10380899 A BG10380899 A BG 10380899A BG 103808 A BG103808 A BG 103808A
Authority
BG
Bulgaria
Prior art keywords
corticosteroid
antagonist
patient
antibody
another
Prior art date
Application number
BG103808A
Other languages
Bulgarian (bg)
Inventor
Les Sekut
Adam Carter
Tariq Ghayur
Subhashis Banerjee
Daniel TRACEY
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/820,692 external-priority patent/US6054487A/en
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of BG103808A publication Critical patent/BG103808A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The methods are used for the treatment of different inflammatory and immunological diseases and disorders. They modulate the patient's reaction against corticostreroids. A form is applied which antagonzes a target regulating the IFN-gamma production together with a corticosteroid so that the patient's reaction to the corticosteroid is modulated in comparison with the individual administration of a corticosteroid. According to an option of implementation the form is IL-18 antagonist. In another option the form is interleucine-12 (IL-12) antagonist. The form can also be NK cellular antagonist. According to another preferable implementation the form is inhibitor of the caspase family protease, preferably ICE inhibitor. In another implemenmtation the foirm is anti- IL-12 monoclonal antibody. The form can be anti-asialo-GM1 antibody or NH1.1 antibody. Other perferable forms are phosphodiesterase IV inhibitors and beta-2 agonists. Pharmaceutical compositions are also developed including a form which antagonizes a target which regulates the production of IFN-gamma organism of the patient together with a corticosteroid and a pharmaceutically acceptable carrier. The preferable composition includes ICE inhibitor, corticosteroid and a pharmaceutically acceptable carrier. 86 claims
BG103808A 1997-03-18 1999-10-13 Methods and compositions for modulation responsiveness to corticosteroids BG103808A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/820,692 US6054487A (en) 1997-03-18 1997-03-18 Methods and compositions for modulating responsiveness to corticosteroids
US1634698A 1998-01-30 1998-01-30
PCT/US1998/004916 WO1998041232A2 (en) 1997-03-18 1998-03-12 Compositions for modulating responsiveness to corticosteroids

Publications (1)

Publication Number Publication Date
BG103808A true BG103808A (en) 2000-07-31

Family

ID=26688484

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103808A BG103808A (en) 1997-03-18 1999-10-13 Methods and compositions for modulation responsiveness to corticosteroids

Country Status (20)

Country Link
EP (1) EP0998300A1 (en)
JP (1) JP2002504091A (en)
KR (1) KR20000076420A (en)
CN (1) CN1269722A (en)
AU (1) AU734756B2 (en)
BG (1) BG103808A (en)
BR (1) BR9810409A (en)
CA (1) CA2282845A1 (en)
DE (1) DE998300T1 (en)
ES (1) ES2146192T1 (en)
HU (1) HUP0104439A3 (en)
ID (1) ID22975A (en)
IL (1) IL131815A0 (en)
NO (1) NO994506L (en)
NZ (1) NZ337769A (en)
PL (1) PL336464A1 (en)
SI (1) SI20110A (en)
SK (1) SK122199A3 (en)
TR (1) TR199902615T2 (en)
WO (1) WO1998041232A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (en) * 1997-10-17 2001-05-30 Smithkline Beecham Corp USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
AU744302B2 (en) * 1997-10-31 2002-02-21 Beth Israel Deaconess Medical Center Use of anti-IL-12 antibodies in transplantation rejection
WO1999025737A1 (en) * 1997-11-19 1999-05-27 Tanox Pharma B.V. Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain
CN1297354A (en) * 1998-03-16 2001-05-30 西托维亚公司 Dipeptide caspase inhibitors and use thereof
EP1140206A4 (en) * 1998-11-27 2002-04-10 Technion Res & Dev Foundation VACCINE BASED ON INTERFERON GAMMA INDUCTION FACTOR AND USE THEREOF FOR PROVIDING PROTECTION IMMUNITY AGAINST MULTIPLE SCLEROSIS
ATE305506T1 (en) * 1998-12-09 2005-10-15 Protein Design Labs Inc USE OF IL-12 ANTIBODIES TO TREAT PSORIASIS
ATE336480T1 (en) 1999-03-16 2006-09-15 Cytovia Inc SUBSTITUTED 2-AMINOBENZAMIN CASPASE INHIBITORS AND THEIR USE
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DE19915465A1 (en) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Use of a caspase inhibitor to inhibit cell proliferation and use of one or more caspase inhibitors to treat diseases based on lymphocyte hyperproliferation or to suppress an immune response by lymphocytes
DE60035037T2 (en) 1999-04-09 2008-01-31 Cytovia, Inc., San Diego CASPASE INHIBITORS AND ITS USE
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
ATE409688T1 (en) 1999-08-27 2008-10-15 Cytovia Inc SUBSTITUTED ALPHA-HYDROXY ACIDS AS CASPASE INHIBITORS AND THEIR USE
WO2001019373A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
NZ520392A (en) 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
ES2267778T3 (en) * 2000-06-06 2007-03-16 Glaxo Group Limited COMPOSITION FOR THE TREATMENT OF CANCER, CONTAINING AN ANTI-NEOPLASTIC AGENT AND A PDE4 INHIBITOR.
WO2001097815A2 (en) * 2000-06-22 2001-12-27 Willy Ben Moussa Ben Mohammed Use of glucocorticosteroids for producing a medicament to treat oligotrichia
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
AU2000270300A1 (en) * 2000-09-13 2002-03-26 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
CZ305653B6 (en) * 2001-01-29 2016-01-27 Merck Serono Sa Pharmaceutical composition
MXPA03010575A (en) * 2001-05-16 2005-03-07 Yeda Res & Dev Use of il-18 inhibitors for the treatement or prevention of sepsis.
RS54274B1 (en) 2001-06-26 2016-02-29 Amgen Fremont Inc. ANGELS FOR OPGL
KR100917082B1 (en) * 2001-10-05 2009-09-15 콤비네이토릭스, 인코포레이티드 Combinations for the treatment of immunoinflammatory disorders
JP2003342196A (en) * 2002-05-31 2003-12-03 Mukku:Kk Composition for intravenous injection, method of production for the same and its preparation
EP1553955A4 (en) * 2002-09-24 2008-11-05 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
WO2005110450A1 (en) * 2004-05-17 2005-11-24 Keio University Medicinal composition and therapeutic method
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
JP5595632B2 (en) * 2004-07-16 2014-09-24 敦生 関山 IL-18 receptor antagonist and pharmaceutical composition comprising said antagonist
US20070287689A1 (en) * 2004-10-13 2007-12-13 Kyowa Hakko Kogyo Co., Ltd. Therapeutic And/Or Preventive Agents For Chronic Skin Diseases
ATE552032T1 (en) 2005-07-14 2012-04-15 Lithera Inc IMPROVED LIPOLYTIC FORMULATION WITH SUSTAINED RELEASE FOR THE AREA TREATMENT OF FAT TISSUE
JP2010506941A (en) * 2006-10-17 2010-03-04 リセラ，インク． Methods, compositions and formulations for the treatment of thyroid ophthalmopathy
NZ578065A (en) 2007-01-16 2012-09-28 Abbott Lab Methods for treating psoriasis with an antibody which binds to an epitope
JP2010522752A (en) 2007-03-29 2010-07-08 アボット・ラボラトリーズ Crystalline anti-human IL-12 antibody
AU2009225797A1 (en) 2008-03-18 2009-09-24 Abbvie Inc. Methods for treating psoriasis
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
CN105832681A (en) 2010-11-24 2016-08-10 纽赛蒂克斯公司 Selective, lipophilic, and long-acting beta agonist mono-therapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
WO2022173923A1 (en) 2021-02-10 2022-08-18 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
MX2024003580A (en) * 2021-09-22 2024-04-05 Iolyx Therapeutics Inc Methods of treating ocular inflammatory diseases.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
EP0416950B1 (en) * 1989-09-08 1993-08-11 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (en) * 1992-07-31 1994-03-31 Glaxo Group Ltd PHARMACEUTICAL FORMULATION IN AEROSOL, CAN SUITABLE TO RELEASE THE FORMULATION AND INHALER OF DOSE DOSE THAT COMPRISES THE CAN.
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
ATE258813T1 (en) * 1995-04-14 2004-02-15 Smithkline Beecham Corp DEVICE FOR THE DOSED INHALATION OF BECLOMETHASONE DIPROPRIONATE

Also Published As

Publication number Publication date
EP0998300A1 (en) 2000-05-10
PL336464A1 (en) 2000-06-19
NO994506L (en) 1999-11-17
CN1269722A (en) 2000-10-11
SK122199A3 (en) 2000-12-11
DE998300T1 (en) 2001-03-01
CA2282845A1 (en) 1998-09-24
AU6760498A (en) 1998-10-12
NO994506D0 (en) 1999-09-17
ES2146192T1 (en) 2000-08-01
ID22975A (en) 1999-12-23
IL131815A0 (en) 2001-03-19
WO1998041232A3 (en) 2000-10-05
BR9810409A (en) 2000-08-22
AU734756B2 (en) 2001-06-21
SI20110A (en) 2000-06-30
WO1998041232A2 (en) 1998-09-24
KR20000076420A (en) 2000-12-26
HUP0104439A3 (en) 2002-08-28
TR199902615T2 (en) 2000-03-21
JP2002504091A (en) 2002-02-05
HUP0104439A2 (en) 2002-04-29
NZ337769A (en) 2002-09-27

Similar Documents

Publication Publication Date Title
BG103808A (en) Methods and compositions for modulation responsiveness to corticosteroids
WO2001019373A3 (en) Methods and compositions for modulating responsiveness to corticosteroids
AU8377698A (en) Inhibitors of p38
HK1022440A1 (en) Combination therapy using a tnf binding protein for treating tnf-mediated diseases
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
MY132496A (en) Inhibitors of p38
MY117696A (en) INHIBITORS OF p38
AU2002211366A1 (en) Human anti-cd40 antibodies
AU1520195A (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
GEP20012442B (en) Irreversible Inhibitors of Tyrosine Kinases
EP0821587A4 (en) Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
Goodrich et al. Effect of intestinal epithelial cell cytokines on mucosal B-cell IgA secretion: enhancing effect of epithelial-derived IL-6 but not TGF-β on IgA+ B cells
AU7239996A (en) Inhibition of tumor necrosis factor alpha
DE69533194D1 (en) PYRAZOLO (3.4g) CHINOXALINE AS A PDGF RECEPTOR PROTEIN TYROSIN KINASE INHIBITOR
WO2003054018A3 (en) Anti-tirc7 antibodies in therapy of inflammatory diseases
MD1521F2 (en) Methods of thrombus forming inhibition, methods of treatment of thrombotic states, pharmaceutical compositions and kit for treatment of thrombotic states
Jaken et al. Dexamethasone inhibition and phorbol myristate acetate stimulation of plasminogen activator in human embryonic lung cells
Haas et al. Angiotensin II-producing enzyme III from acidified serum of nephrectomized dogs
Shibahara Classical treatments for infertile men with anti-sperm antibody (ASA)
ATE298244T1 (en) MONOCLONAL ANTIBODIES WITH SELECTIVE BINDING TO VGF AND USE FOR THE TREATMENT OF VGF DISEASES
Singer et al. Interleukin-1 receptor-ligand interactions modulate interstitial collagenase-1 production by human endometrial fibroblasts
Cecchi et al. Painless treatment of hydrocele: EMLA cream anaesthesia and fibrin adhesive sclerotherapy
Dillon et al. Changes in electrophoretic patterns of sera in patients with multiple myeloma treated with urethane